A long Covid collaborative kicks off with $15M to study causes of lingering disease, conduct clinical trials

Kyle LaHucik

Senior Reporter

The Covid-19 pandemic has left millions of people with lingering symptoms months after initial diagnosis, and none of the handful of biopharmas that have attempted …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A long Covid collaborative kicks off with $15M to study causes of lingering disease, conduct clinical trials

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

White House threatens ‘most favored nation’ plan to lower US drug prices, but many questions remain

Trump says he'll sign order on 'most favored nation' drug price plans Monday

Lilly says further head-to-head trial data back Zepbound over Novo’s Wegovy

Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment

From deal to disaster: Drugmakers face a changed Washington as Trump embraces ‘most favored nation’ prices

Revolution’s KRAS drugs appear competitive in several lung cancer settings

A long Covid col­lab­o­ra­tive kicks off with $15M to study caus­es of lin­ger­ing dis­ease, con­duct clin­i­cal tri­als

Senior Reporter

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

A long Covid collaborative kicks off with $15M to study causes of lingering disease, conduct clinical trials